RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Realcan Pharmaceutical Group Co - Stock

Realcan Pharmaceutical Group Co P/E 2024

Realcan Pharmaceutical Group Co P/E

266.61

Ticker

002589.SZ

ISIN

CNE1000013X5

As of Jul 1, 2024, Realcan Pharmaceutical Group Co's P/E ratio was 266.61, a -8,106.31% change from the -3.33 P/E ratio recorded in the previous year.

The Realcan Pharmaceutical Group Co P/E history

Realcan Pharmaceutical Group Co Aktienanalyse

What does Realcan Pharmaceutical Group Co do?

Realcan Pharmaceutical Group Co. Ltd is a Chinese pharmaceutical company based in the city of Chengdu. The company was founded in 2009 and has since built a deep knowledge and understanding of the pharmaceutical industry in the Chinese market. Since its inception, the company has developed a wide range of drugs and health products. Realcan Pharmaceutical Group Co. Ltd has established itself as one of the largest and most reliable pharmaceutical companies in China, specializing in the development, manufacturing, and marketing of pharmaceuticals. The business model of Realcan Pharmaceutical Group Co. Ltd is based on a variety of growth drivers, including entering new markets and developing new products. The company has always focused on leveraging the experience and expertise of its employees to deliver innovations and high-quality products that have a positive impact on consumer health. The company places the highest value on the quality, safety, and effectiveness of its products and services. Realcan Pharmaceutical Group Co. Ltd offers a wide range of products, ranging from drugs and medications to health products and supplements. The company specializes in various areas, including oncology, dermatology, cardiology, neurology, respiratory diseases, gastroenterology, and endocrinology. Several products from Realcan have already received approval from the Chinese health authority and are available on the market. Some of the company's most well-known products include the anti-tumor drugs Nifuratel and Nifuratrone, the cardiology product Cardio Protect, and the neurology product Neuro Relief. Realcan Pharmaceutical Group Co. Ltd also specializes in the production of traditional Chinese medicine and herbal medicine. Traditional Chinese medicine is gaining increasing importance in the Chinese market as it is considered an effective alternative to Western medicine. Realcan Pharmaceutical Group Co. Ltd is committed to promoting research and development in the field of traditional Chinese medicine. The company works closely with universities and other research institutions to develop effective and safe herbal medicine. Realcan Pharmaceutical Group Co. Ltd also specializes in entering international markets. The company exports its products to various countries, including the United States, Australia, France, India, and Japan. The company places great emphasis on complying with international standards and ensuring the safety and quality of its products. In summary, Realcan Pharmaceutical Group Co. Ltd is an innovative Chinese pharmaceutical company that offers a wide range of pharmaceutical products and services. The company has established itself as a reliable brand in the field of drug development and manufacturing and is committed to adhering to global standards to strengthen customer trust. Realcan Pharmaceutical Group Co. Ltd will continue to play an important role in the Chinese and international markets and consolidate its leadership position as a reliable and innovative pharmaceutical company. Realcan Pharmaceutical Group Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Realcan Pharmaceutical Group Co's P/E Ratio

The Price to Earnings (P/E) Ratio of Realcan Pharmaceutical Group Co is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Realcan Pharmaceutical Group Co's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Realcan Pharmaceutical Group Co is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Realcan Pharmaceutical Group Co’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Realcan Pharmaceutical Group Co Stock

What is the price-to-earnings ratio of Realcan Pharmaceutical Group Co?

The price-earnings ratio of Realcan Pharmaceutical Group Co is currently 266.61.

How has the price-earnings ratio of Realcan Pharmaceutical Group Co changed compared to last year?

The price-to-earnings ratio of Realcan Pharmaceutical Group Co has increased by -8,106.31% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Realcan Pharmaceutical Group Co high compared to other companies?

Yes, the price-to-earnings ratio of Realcan Pharmaceutical Group Co is high compared to other companies.

How does an increase in the price-earnings ratio of Realcan Pharmaceutical Group Co affect the company?

An increase in the price-earnings ratio of Realcan Pharmaceutical Group Co would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Realcan Pharmaceutical Group Co affect the company?

A decrease in the price-earnings ratio of Realcan Pharmaceutical Group Co would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Realcan Pharmaceutical Group Co?

Some factors that influence the price-earnings ratio of Realcan Pharmaceutical Group Co are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Realcan Pharmaceutical Group Co pay?

Over the past 12 months, Realcan Pharmaceutical Group Co paid a dividend of 0.01 CNY . This corresponds to a dividend yield of about 0.41 %. For the coming 12 months, Realcan Pharmaceutical Group Co is expected to pay a dividend of 0.01 CNY.

What is the dividend yield of Realcan Pharmaceutical Group Co?

The current dividend yield of Realcan Pharmaceutical Group Co is 0.41 %.

When does Realcan Pharmaceutical Group Co pay dividends?

Realcan Pharmaceutical Group Co pays a quarterly dividend. This is distributed in the months of July, July, August, July.

How secure is the dividend of Realcan Pharmaceutical Group Co?

Realcan Pharmaceutical Group Co paid dividends every year for the past 0 years.

What is the dividend of Realcan Pharmaceutical Group Co?

For the upcoming 12 months, dividends amounting to 0.01 CNY are expected. This corresponds to a dividend yield of 0.41 %.

In which sector is Realcan Pharmaceutical Group Co located?

Realcan Pharmaceutical Group Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Realcan Pharmaceutical Group Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Realcan Pharmaceutical Group Co from 6/4/2024 amounting to 0.013 CNY, you needed to have the stock in your portfolio before the ex-date on 6/4/2024.

When did Realcan Pharmaceutical Group Co pay the last dividend?

The last dividend was paid out on 6/4/2024.

What was the dividend of Realcan Pharmaceutical Group Co in the year 2023?

In the year 2023, Realcan Pharmaceutical Group Co distributed 0.018 CNY as dividends.

In which currency does Realcan Pharmaceutical Group Co pay out the dividend?

The dividends of Realcan Pharmaceutical Group Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Realcan Pharmaceutical Group Co

Our stock analysis for Realcan Pharmaceutical Group Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Realcan Pharmaceutical Group Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.